Abstract
T helper (Th)17 cells and other interleukin (IL)-17-producing cells are supposed to play critical roles in several human immune-mediated diseases, including Crohn’s disease (CD) and ulcerative colitis (UC), the main forms of inflammatory bowel diseases (IBD) in man. Th17 cells infiltrate massively the inflamed intestine of IBD patients and in vitro and in vivo studies have shown that Th17-type cytokines may trigger and amplify multiple inflammatory pathways. Nonetheless, some Th17-related cytokines, such as interleukin (IL)-17A and IL-22, may target gut epithelial cells and promote the activation of counter-regulatory mechanisms. This observation together with the demonstration that Th17 cells are not stable and can be converted into either regulatory T cells or Th1 cells if stimulated by immune-suppressive (e.g. TGF-β1) or inflammatory (e.g. IL-12, IL-23) cytokines have contributed to advance our understanding of mechanisms that regulate mucosal homeostasis and inflammation in the gut.
Current Molecular Medicine
Title:Th17-Related Cytokines in Inflammatory Bowel Diseases: Friends or Foes?
Volume: 12 Issue: 5
Author(s): I. Monteleone, M. Sarra, F. Pallone and G. Monteleone
Affiliation:
Abstract: T helper (Th)17 cells and other interleukin (IL)-17-producing cells are supposed to play critical roles in several human immune-mediated diseases, including Crohn’s disease (CD) and ulcerative colitis (UC), the main forms of inflammatory bowel diseases (IBD) in man. Th17 cells infiltrate massively the inflamed intestine of IBD patients and in vitro and in vivo studies have shown that Th17-type cytokines may trigger and amplify multiple inflammatory pathways. Nonetheless, some Th17-related cytokines, such as interleukin (IL)-17A and IL-22, may target gut epithelial cells and promote the activation of counter-regulatory mechanisms. This observation together with the demonstration that Th17 cells are not stable and can be converted into either regulatory T cells or Th1 cells if stimulated by immune-suppressive (e.g. TGF-β1) or inflammatory (e.g. IL-12, IL-23) cytokines have contributed to advance our understanding of mechanisms that regulate mucosal homeostasis and inflammation in the gut.
Export Options
About this article
Cite this article as:
Monteleone I., Sarra M., Pallone F. and Monteleone G., Th17-Related Cytokines in Inflammatory Bowel Diseases: Friends or Foes?, Current Molecular Medicine 2012; 12 (5) . https://dx.doi.org/10.2174/156652412800620066
DOI https://dx.doi.org/10.2174/156652412800620066 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial: [Hot Topic: Keeping Track of an Expanding Subject - Recent Trends in Immunology and their Clinical Implications]
Current Pharmaceutical Design Targeting the Prokineticin System to Control Chronic Pain and Inflammation
Current Medicinal Chemistry Possible Roles of Microglial Cells for Neurotoxicity in Clinical Neurodegenerative Diseases and Experimental Animal Models
Inflammation & Allergy - Drug Targets (Discontinued) CD6 as a Cell Surface Receptor and As a Target for Regulating Immune Responses
Current Drug Targets Targeting Regulatory T Cells in the Treatment of Type 1 Diabetes Mellitus
Current Molecular Medicine Nicotinamide Phosphoribosyltransferase as a Target in Inflammation- Related Disorders
Current Topics in Medicinal Chemistry Drug Discovery in Enteroviral Infections
Infectious Disorders - Drug Targets The Potential Therapeutic Role of the HMGB1-TLR Pathway in Epilepsy
Current Drug Targets Nutraceuticals against Neurodegeneration: A Mechanistic Insight
Current Neuropharmacology Interleukin-7: a key Mediator in T Cell-driven Autoimmunity, Inflammation, and Tissue Destruction
Current Pharmaceutical Design Discovery of GPCR Ligands by Molecular Docking Screening: Novel Opportunities Provided by Crystal Structures
Current Topics in Medicinal Chemistry Heparanase Patents: Dim Past and Bright Future
Recent Patents on Inflammation & Allergy Drug Discovery The AKT Axis as a Therapeutic Target in Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Autoimmune Diseases and Atherosclerosis: The Inflammatory Connection
Current Immunology Reviews (Discontinued) Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94
Current Topics in Medicinal Chemistry Tianeptine: A Novel Atypical Antidepressant that May Provide New Insights into the Biomolecular Basis of Depression
Recent Patents on CNS Drug Discovery (Discontinued) GPR30 Forms an Integral Part of E2-Protective Pathway in Experimental Autoimmune Encephalomyelitis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Targeting Microglial Polarization to Improve TBI Outcomes
CNS & Neurological Disorders - Drug Targets The Regulation of Neuroimmune-Endocrine Interactions: Mechanisms,Molecular Pathways Unraveled and the Pivotal Role of Cytokines – A Unsung Putative Bidirectional Interdependence between the Immune and Neuroendocrine Interfaces
Current Immunology Reviews (Discontinued) Erythropoietin Signaling and Neuroprotection
Current Signal Transduction Therapy